Results 21 to 30 of about 1,262,540 (308)
Frontiers in Pharmacology, 2022 Objective: Meta analysis was used to explore the efficacy and safety of Sintilimab in the treatment of cancer.Methods: The databases of CNKI, VIP, Wanfang Data, PubMed, ScienceDirect, the Cochrane Library and EMBASE were searched by computer to collect ...
Ziqi Ye +6 more
doaj +1 more source
Infectious Diseases and Therapy, 2023 Introduction Talaromyces marneffei (T. marneffei), a dimorphic fungus, causes local or disseminated infection in humans. We aimed to analyze the clinical characteristics, prognostic factors, and survival outcomes of patients with T.
QingLiang Yu +14 more
doaj +1 more source
Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma [PDF]
, 2019 BACKGROUND: Meningiomas are the most common primary tumors of the central nervous system. In patients with WHO grade I meningiomas no adjuvant therapy is recommended after resection.
Acker, Güliz +9 more
core +1 more source
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]
, 2018 Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John +8 more
core +1 more source
Indonesian Journal of Cancer, 2021 Background: This study was conducted to determine the association between clinical characteristics, progression-free survival (PFS), and 3-year survival in patients with epithelial ovarian cancer who underwent surgery in 2016-2017 at RSUD Dr.
Brahmana Askandar Tjokroprawiro +2 more
doaj +1 more source
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients [PDF]
, 2016 Objective: Topoisomerase 1 (topo-1) is an important target for the treatment of metastatic colorectal cancer (CRC). The aim of the present study was to evaluate the correlation between topo-1 single-nucleotide polymorphisms (SNPs) and clinical outcome in
Crea, F. +11 more
core +1 more source
Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival [PDF]
JNCI: Journal of the National Cancer Institute, 2015 Broglio and Berry (2009) examined the impact of survival postprogression (SPP) on overall survival (OS) when progression-free survival (PFS) was used to assess treatment effect in metastatic cancer. Their simulation studies found no statistical difference in OS because of dilution effect from SPP, although there was a statistical difference in PFS ...
Morita, S, Sakamaki, K, Yin, G
openaire +4 more sources
Outcome of Primary CNS Lymphoma; A Retrospective Analysis
Asian Pacific Journal of Cancer Care, 2022 Background: Rituximab along with high dose Methotrexate is nowadays the standard of care in treatment of PCNSL. We report the retrospective analysis of PCNSL patients who were treated with and without Rituximab at Aga Khan University Hospital, Karachi ...
Mehwish Shahzadi +3 more
doaj +1 more source
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy [PDF]
, 2015 INTRODUCTION: Mutations (MT) of the KRAS gene are the most common mutation in non-small cell lung cancer (NSCLC), seen in about 20-25% of all adenocarcinomas. Effect of KRAS MT on response to cytotoxic chemotherapy is unclear.
Aggarwal, Charu +8 more
core +4 more sources
Prognostic factors and survival study in high-grade glioma in a hospital in Lima, Peru
Revista de la Facultad de Medicina Humana, 2020 Introduction: Gliomas are primary tumors of the central nervous system. They are classifiedfrom grade I-IV, with high grade III and IV being the most frequent and with poor prognosis. Objective: To determine the prognostic factors of survival in patients
Paul Méndez-Aguilar +1 more
doaj +1 more source